Table 1

Inhibition of cell proliferation by CDDO

All cells were obtained from American Type Culture Collection, except as otherwise noted. They were grown under standard conditions in DMEM, DMEM/F12, or RPMI 1640 plus 5–10% fetal bovine serum. CDDO, over the dose range of 10−6–10−10 m, was added to cultures at the time of seeding. Three or 4 days later, cells were treated with [3H]thymidine for 2 h (12 h in the case of leukemia cells), and then incorporation was measured.

CellCell typeIC50 (m)
MCF-7ERa positive breast carcinoma3 × 10−8
MDA-MB-231ER negative breast carcinoma1 × 0−6
21-MT-1bER negative breast carcinoma2 × 10−7
21-MT-2bER negative breast carcinoma3 × 10−7
21-NTbER negative breast carcinoma1 × 10−6
21-PTbER negative breast carcinoma3 × 10−7
THP-1Monocytic leukemia5 × 10−8
U937Monocytic leukemia2 × 10−7
HL-60Myelocytic leukemia1 × 10−7
NB4cPromyelocytic leukemia4 × 10−8
AML 193Acute myelocytic leukemia4 × 10−7
KG-1Acute myeloid leukemia2 × 10−7
ML-1dMyeloblastic leukemia1 × 10−7
NT2/D1Embryonal carcinoma1 × 10−7
A2058Melanoma2 × 10−7
MDA-MB-468eER negative breast carcinoma2 × 10−7
SW626eOvarian carcinoma3 × 10−7
AsPc-1ePancreatic carcinoma1 × 10−7
CAPAN-1ePancreatic carcinoma3 × 10−7
  • a ER, estrogen receptor.

  • b From Vimla Band, Dana-Farber Cancer Institute, Harvard University, Boston, MA (presently at Tufts University School of Medicine, Boston, MA).

  • c From M. Lanotte, Institut National de la Santé et de la Recherche Medicale, Paris, France.

  • d From Ruth Craig, Dartmouth Medical School.

  • e These cells all have Smad4/DPC4 mutations (24).